Previous 10 | Next 10 |
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congr...
Freeline Therapeutics (NASDAQ:FRLN) said on Tuesday it had begun dosing the second cohort in its Phase 1/2 dose confirmation trial of FLT180a in people with hemophilia B. The company said patients in cohort two will receive the same low dose (7.7e11 vg/kg) of FLT180a and optimized p...
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen Cohort one efficacy and safety data to be presented at ISTH Congre...
Wedbush Securities has initiated Sangamo Therapeutics (NASDAQ:SGMO) with a hold rating noting that while it sees promise in isaralgagene civaparvovec for Fabry disease, the candidate needs to demonstrate better durable efficacy and safety compared to current treatments. The firm has a $5 pric...
U.K.-based clinical-stage biotech Freeline Therapeutics (NASDAQ:FRLN) dropped ~6% in the post-market Friday after the company said that it is not currently in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq. Informing about its non-complia...
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul Schneider, and six other newly hired employees non-statutory options to purchase an aggreg...
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from the Nasdaq Stock Market LLC (“Nasdaq”...
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...
Freeline Therapeutics press release (NASDAQ:FRLN): Q1 GAAP EPS of -$0.63. Cash and cash equivalents were $113.1 million as of March 31, 2022, as compared to $117.7 million as of year-end 2021. For further details see: Freeline Therapeutics GAAP EPS of -$0.63
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership team LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holding...
News, Short Squeeze, Breakout and More Instantly...
Freeline Therapeutics Holdings plc Company Name:
FRLN Stock Symbol:
NASDAQ Market:
Freeline Therapeutics Holdings plc Website:
Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline’s GBA1 Parkinson’s disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the...
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
Please find enclosed the presentation of Frontline plc´s fourth quarter 2023 results to be held on the webcast / conference call 29 February, 2024 at 15:00 CET. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act ...